Publications by authors named "Socratous A"
Purpose: To assess the association between neoadjuvant therapy and overall survival (OS) in patients with left-sided resectable pancreatic cancer (RPC) compared to upfront surgery.
Background: Left-sided pancreatic cancer is associated with worse OS compared to right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with RPC, current randomized trials included mostly patients with right-sided RPC.
Background: Data on the efficacy and safety of screening for prostate cancer with magnetic resonance imaging (MRI) are needed from studies of follow-up screening.
Methods: In a population-based trial that started in 2015, we invited men who were 50 to 60 years of age to undergo prostate-specific antigen (PSA) screening. Men with a PSA level of 3 ng per milliliter or higher underwent MRI of the prostate.
Background: Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown.
Methods: We invited 37,887 men who were 50 to 60 years of age to undergo regular prostate-specific antigen (PSA) screening.
Background: The Göteborg 2 prostate cancer (PC) screening (G2) trial evaluates screening with prostate-specific antigen (PSA) followed by magnetic resonance imaging (MRI) in case of elevated PSA levels.
Objective: To assess the safety of using a 2-yr interval in men who were previously screened positive with PSA but had negative MRI or positive MRI with a negative biopsy.
Design, Setting, And Participants: A total of 61 201 men aged 50-60 yr were randomized and 38 366 were invited for screening (years 2015-2020).
Background: The acceptance of ABO-incompatible (ABOi) liver grafts will expand the donor pool for a patient in urgent need for a liver transplantation (LT). Here we report our results with emergency ABOi DD (deceased donor) LT using rituximab and antigen specific immunoadsorption.
Patients And Methods: 2009 to 2019 we performed 20 ABOi DD LTs (adults = 17, children = 3) for patients in urgent need for a LT.
Article Synopsis
- The PIRADS Steering Committee supports the use of biparametric MRI (bpMRI) in low-risk settings for prostate cancer screening, as it provides a cost-effective alternative to multiparametric MRI (mpMRI) without the need for intravenous contrast.
- A study involving 551 participants found that bpMRI detected nearly the same amount of prostate cancer cases (15.1%) compared to mpMRI (15.2%), with bpMRI resulting in fewer false positives.
- The results suggest that in prostate cancer screening, bpMRI is as effective as mpMRI while being more efficient and less invasive, highlighting the importance of considering costs alongside detection sensitivity.
Background: Magnetic resonance imaging (MRI) and targeted biopsies (TB) have shown potential to more accurately detect significant prostate cancer compared with prostate-specific antigen (PSA) and systematic biopsies (SB).
Objective: To compare sequential screening (PSA+MRI) with conventional PSA screening.
Design, Setting, And Participants: Of 384 attendees in the 10th screening round of the Göteborg randomised screening trial, 124 men, median age 69.